Stephen Chung Lee

Dr. Stephen Chung Lee

University of California - Irvine
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in Mental Health Clinician
Verified
Journal Article
Open access
PDF file
JNJulie Nguyen
Julie Nguyen
SLStephen Chung Lee
Stephen Chung Lee
DADennis Ankrah
Dennis Ankrah
EKErin Knox
Erin Knox
Methamphetamine is an addictive stimulant that may induce symptoms of agitation and psychosis. The estimated rate of methamphetamine use is 6.6 per 1000 people. Currently, no treatment guidelines exist to support the optimal management of patients presenting with methamphetamine-induced agitation. Emergency department (ED) providers may prescribe various benzodiazepines (BZDs) and antipsychotics (APs) as first-line agents to stabilize these agitated patients. This study aims to determine the effectiveness of a protocol to guide management of this condition. This was a retrospective, pre- and poststudy conducted from July 2020 to March 2021 at a large academic medical center. A multidisciplinary protocol was designed to help manage methamphetamine-induced agitation in the ED. The primary outcome of the study was a reduction in the number of BZDs and APs used for the treatment of methamphetamine-induced agitation. This was measured by the incidence of overprescribing, defined as 3 or more APs or BZDs administered within 30 minutes. Secondary outcomes included the use of physical restraints, ED length of stay, and adverse events. We did not observe a significantly lower incidence of overprescribing, adverse events, or ED length of stay when comparing pre- and postprotocol groups. A subgroup analysis demonstrated that when protocol was followed, there was a statistically significant reduction in overprescribing (P = .001). We did not find any differences among our primary and secondary outcomes, which may be attributed to protocol nonadherence. Full compliance to the protocol may reduce the rate of overprescribing APs or BZDs in patients with methamphetamine-induced agitation.

27 December 2021 in Healthcare
Verified
Journal Article
Open access
PDF file
DPDanny Pham
Danny Pham
SWSandy Wong
Sandy Wong
Christina Thuong NguyenChristina Thuong Nguyen
Christina Thuong Nguyen
SLStephen Chung Lee
Stephen Chung Lee
Kimberly WonKimberly Won
Kimberly Won
The coronavirus disease 2019 (COVID-19) pandemic has prompted the creation of new therapies to help fight against the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Bamlanivimab is a SARS-CoV-2 monoclonal antibody that is administered as an intravenous infusion to ambulatory patients with mild or moderate COVID-19, but a concern that arose was deciding the optimal location for patients to receive the medication. This report describes the development and implementation of a bamlanivimab infusion center in the emergency department of three hospitals in Orange County, California, shortly after bamlanivimab received emergency use authorization. As a result, a total of 601 patients received bamlanivimab in one of these three emergency departments between December 2020 to April 2021. The emergency department was shown to be an optimal setting for administration of bamlanivimab due to its convenience, accessibility, and capabilities for monitoring patients.

11 May 2023 in Western Journal of Emergency Medicine
Verified
Journal Article
Open access
PDF file
DPDanny Hieu Pham
Danny Hieu Pham
SLStephen Chung Lee
Stephen Chung Lee
SASadaf Abrishami
Sadaf Abrishami
BCBharath Chakravarthy
Bharath Chakravarthy
SSSoheil Saadat
Soheil Saadat
Introduction: Urinary tract infections (UTI) are a common reason for an emergency department (ED) visit. The majority of these patients are discharged directly home without a hospital admission. After discharge, emergency physicians have traditionally managed the care of the patient if a change is warranted (as a result of urine culture results). However, in recent years clinical pharmacists in the ED have largely incorporated this task into their standard practice. In our study, we aimed to 1) describe our unique process in having a pharmacist-led, urinary culture follow-up, and 2) compare it to our previous, more traditional process.Methods: In our retrospective study, we evaluated the impact of a pharmacist-led, urinary culture follow-up program after discharge from the ED. We included patients prior to and after the implementation of our new protocol to compare the differences. The primary outcome was time to intervention after urine culture result was released. Secondary outcomes included rate of documentation of intervention, appropriate interventions made, and repeat ED visits within 30 days.Results: We included a total of 265 unique urine cultures from 264 patients in the study: 129 cultures were from the period prior to implementation of the protocol, and 136 were from the post-implementation period. There were no significant differences between pre- and post-implementation groups for the primary outcome. Appropriate therapeutic intervention based on positive urine culture results was 16.3% in the pre-implementation group vs 14.7% in the post-implementation group (P=0.72). Secondary outcomes of time to intervention, documentation rates, and readmissions were similar between both groups.Conclusion: Implementation of a pharmacist-led, urinary culture follow-up program after discharge from the ED led to similar outcomes as a physician-run program. An ED pharmacist can successfully run a urinary culture follow-up program in an ED without physician involvement.

1 October 2017 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
SLStephen Chung Lee
Stephen Chung Lee
DFDouglas N Fish
Douglas N Fish
GBGerard Barber
Gerard Barber
MBMichelle Barron
Michelle Barron
Community-acquired (CA) UTI caused by ESBL-producing pathogens pose challenges related to initial antibiotic (AB) selection. Better characterization of AB susceptibilities in CA ESBL infections may improve empiric drug selection for outpatient therapy. The objectives of this study were to describe AB susceptibilities of isolates in CA ESBL UTI and provide recommendations for appropriate treatment at our institution. Adult patients with CA ESBL UTI (cystitis) from 2009 through 2013 were retrospectively matched 1:1 with a control group of non-ESBL CA UTI based on age within 5 years, gender, and organism. The primary outcome in this phase of the study was description of AB susceptibilities in CA ESBL UTI vs. controls. Secondary outcomes were comparison of appropriate initial AB therapy (defined as concordance of initial AB with in vitro susceptibilities) and development of recommendations for initial antibiotics for CA UTI. Eighty-five patients were matched into each of the ESBL and non-ESBL CA UTI groups. E. coli was the pathogen in 94% of ESBL UTIs and 96% of controls. Patients with ESBL UTI most often received ceftriaxone or oral β-lactam (BL, 31%), fluoroquinolone (FQ, 27%), trimethoprim/sulfamethoxazole (TMP/SMX, 14%), or nitrofurantoin (NF, 14%); controls were similar. Besides non-carbapenem BLs, ESBL producers were significantly more resistant to FQs (78% resistant), NF (16%), TMP/SMX (60%), gentamicin (33%), and doxycycline (78%) vs. controls (P < 0.01 for each). Ertapenem and amikacin had 100% and 96% susceptibility, respectively. Initial AB were discordant in 64% of ESBL UTI vs. 14% of controls (OR 11.0, 95% CI 5.0–24.3; P < 0.0001). FQs and TMP/SMX were discordant in 83% and 42% of ESBL UTI, respectively, while NF was concordant in 100% of patients with ESBL UTI and 89% of controls. Patients with CA ESBL UTI were significantly more likely to receive inappropriate initial AB therapy. Although ESBL-producing strains were resistant to multiple AB classes, NF retained activity against 84% of ESBL isolates and was associated with appropriateness of initial therapy in 100% of patients with ESBL UTI. Nitrofurantoin is an appropriate oral option for treatment of CA UTI, even in patients with ESBL infection. D. N. Fish, Merck & Co.: Grant Investigator, Research grant M. Barron, Merck & Co.: Grant Investigator, Research grant

1 October 2017 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
SLStephen Chung Lee
Stephen Chung Lee
DFDouglas N Fish
Douglas N Fish
GBGerard Barber
Gerard Barber
MBMichelle Barron
Michelle Barron
Background Community-acquired (CA) infections caused by ESBL-producing pathogens are becoming more common. Risk factors (RFs) for CA ESBLs have not been as extensively studied and remain relatively undefined. Recognition of patient-specific RFs for CA ESBL infections such as UTI can potentially improve patient outcomes through selection of more appropriate initial drug therapy. The objectives of this study were to identify RFs and associated treatment outcomes for CA UTI involving ESBLs. Methods Adult patients with CA ESBL UTI (cystitis) seen in the Emergency Department (ED) from 2009 through 2013 were retrospectively matched 1:1 with a control group of non-ESBL CA UTI based on age within 5 years, gender, and organism. The primary outcome was identification of RFs predictive of CA ESBL UTI. Secondary outcomes included comparison of ESBLs and controls in risk of inappropriate initial antibiotic therapy and need for additional follow-up to healthcare facilities (clinics, ED) within 14 days of initial treatment. Results Eighty-five patients were matched into each group. Compared with controls, CA ESBL UTI was associated with nursing home stay (P = 0.04), congestive heart failure (CHF, P = 0.04), hospitalization within the previous year (P = 0.04), and receipt of either any antibiotics or specifically, fluoroquinolones within the previous 3 months (P < 0.01 for both) by univariate analysis. Multivariate logistic regression identified hospitalization within 1 year (OR 3.8, 95% CI 1.7–8.7; P < 0.001), antibiotics within 3 months (OR 3.5, 95% CI 1.7–7.6; P < 0.001), and CHF (OR 4.9, 95% CI 1.3–24.7; P = 0.02) as significant RFs for ESBL CA UTI. Patients with CA ESBL infections were more likely to receive inappropriate initial antibiotics (OR 8.9, 95% CI 4.2–18.6; P < 0.0001) and, if treated inappropriately, to require repeat visits to healthcare facilities within 14 days (OR 11.4, 95% CI 2.6–50.8). Conclusion Previous hospitalization, previous antibiotics, and CHF were RFs associated with CA ESBL UTI. These patients were significantly more likely to be treated inappropriately and to require additional healthcare follow-up. Recognition of RFs for CA ESBL UTI may facilitate appropriate ED-based management and avoid additional resource utilization. Disclosures D. N. Fish, Merck & Co.: Grant Investigator, Research grant M. Barron, Merck & Co.: Grant Investigator, Research grant